This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Bheemashankar Kulkarni: Innovator in Pharmaceutical Chemistry
Introduction
Bheemashankar Kulkarni is a notable inventor based in Karnataka, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific receptors associated with various diseases. His work is characterized by a commitment to innovation and a focus on improving therapeutic options for patients.
Latest Patents
Kulkarni holds a patent for "1-Substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as EP4 receptor antagonists." This invention provides a compound represented by a specific formula, which exhibits EP4 receptor antagonistic action. It is useful as an agent for the prophylaxis or treatment of EP4 receptor-associated diseases, including rheumatoid arthritis, aortic aneurysms, endometriosis, ankylosing spondylitis, and inflammatory breast cancer. He has 1 patent to his name.
Career Highlights
Bheemashankar Kulkarni is currently associated with Takeda Pharmaceutical Company Limited, where he continues to engage in innovative research and development. His work at Takeda emphasizes the importance of creating effective treatments for complex medical conditions.
Collaborations
Kulkarni has collaborated with notable colleagues, including Anil Panmand and Anil M Deshpande. These collaborations have contributed to the advancement of research and the development of new therapeutic agents.
Conclusion
Bheemashankar Kulkarni is a distinguished inventor whose work in pharmaceutical chemistry has the potential to impact the treatment of various diseases significantly. His innovative approach and dedication to research exemplify the spirit of invention in the medical field.